AUA 2022 Press Release

REVIEW UroToday

Viewing 1-14 of 14 articles

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

Urologists Share Latest Developments in Prostate Cancer Research

New Research on Erectile Dysfunction and Penis Transplantation to be Presented at Upcoming AUA Annual Meeting

Urologists Explore the Role of Robotics, Equity, Exercise and Medicine on Bladder Cancer

Urologists Examine Role of Pollutants, Medications and Testosterone on Men’s Health

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

Social Networks Proliferate Urological Health Misinformation

Blue Earth Diagnostics Announces Additional Results from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

Studies Debunk COVID-19 Fertility & Transplant Concerns; Long-term Impact of COVID Yet to be Realized in Prostate & Bladder Cancer Patients

Should Urologists Recommend Vibrators for Pelvic Health? Female Genitourinary and Sexual Health Explored at AUA Annual Meeting

Pathnostics to Present New Real-World Data Analysis of its Guidance UTI Precision Diagnostic Test at the 2022 American Urology Association Annual Meeting

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting